AMN107 (Tasigna) now open at Fox Chase Cancer Center

The AMN107 phase III trial is now open at Fox Chase. The contact number is 1-888-FOXCHASE. Patients will be seen every two weeks for the first two months and every two months thereafter. They will be randomized to receive either AMN107 at 400 mg twice a day or best supportive care. Best supportive care allows the treating physician to continue administering Gleevec, Sutent, or other supporting care, however, the patient will be allowed to cross over to receive AMN107 at time of progression. The AMN107 phase III trial is not expected to open at Dana-Farber for several weeks. Between eight and 12 sites are expected to open in the United States and three are expected to open in Canada. We understand there are several sites open in Europe as well.